CNWL NHS Foundation Trust
London, United Kingdom
NCT Number: NCT02053987
An Early Supported Discharge (ESD) service for stroke is an evidence based intervention that aims to enable a particular group of patients who have a mild to moderate stroke to be discharged from hospital early and receive the same intensity of rehabilitation in their home. Analysis of almost 1600 patients has demonstrated that ESD can reduce long term dependency, decrease admission to institutionalized care as well as shorten hospital stay. This model has also been shown to reduce death and institutionalized care at five years (Fjaetoft et al, 2011) and has been shown to be cost effective (Saka, 2005.) A study by National Heath Service (NHS) London showed that patient outcomes has not been affected by being treated at home and that there have not been an increase in readmissions due to the setting up of an ESD service.
However, those with moderate to severe strokes are often not eligible for ESD rehabilitation.
This study aims to offer twenty Camden residents an Enhanced Early Supported Discharge service in which stroke survivors with moderate to severe impairments are eligible. Participants will be recruited from the University College London Hospital (UCLH)l Hyper Acute Stroke Unit and acute stroke units at UCLH and the Royal Free Hospital.
This study will compare health and economic outcomes of early Multidisciplinary stroke rehabilitation in the community compared to traditional inpatient and community Multidisciplinary rehabilitation for people with moderate to severe post stroke impairments.
We will also collect the views of the participants and their carers regarding being treated at home.
The objectives are to discover:
1. What impact does the implementation of an Enhanced ESD service for stroke survivors with moderate to severe impairments have on clinical and cost outcomes compared to an unchanged care pathway in a neighbouring borough? 2. What are the staff, participant and carer views and experiences of an Enhanced ESD service?
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Not applicable
London, United Kingdom
Control Group The control group will comprise those who are not eligible as they are registered with a GP in the London borough of Islington. Islington residents have been chosen as a control group as currently there is no ESD service for patients to be referred to. Rehabilitation therefore takes place as an inpatient with community follow up. The boroughs of Camden and Islington are comparable in terms of ethnic diversity, size, stroke prevalence and age (SEPHO, 2013.) The control group will not be matched to demographics such as age and gender due to the fact that we are unable to predict this information. We will gather information regarding type of stroke, stroke severity and demographics so that this can be compared as much as possible during the analysis.
Consent will be obtained to collect outcome measure data from the control group and their carer's. Local agreement is in place to share their anonymised data for the purposes of the research. The data will be collected by staff on the Acute Stroke Units and by a link individual within Islington Community Services. The outcome measures collected are the same as those currently being collected along the stroke pathway in London. The Caregiver Strain Index and EQ5D are not routinely collected.
A similar number of patients will be identified over the same timescale as the research group and will be subject to the same battery of outcomes due to standardisation across the stroke pathway in London hospitals. Local agreement will be met regarding the six month review outcomes.
Data will be collected within five days post stroke, at approximately nine weeks post stroke and at six months post stroke.
Cost savings The management of acute stroke and ACS has been revolutionised in Camden over the last 5 years. Patients, when identified are transferred by London Ambulance service to UCLH or Royal Free acute trusts. Since the centralisation of Hyper Acute services, the mortality and morbidity for both conditions has dropped (Hunter et al, 2013.) The study will include a comprehensive assessment of cost effectiveness which will include direct and indirect health care costs and social care costs.
Locally the Enhanced ESD service could release acute stroke resources and free monies associated with these, improve access to specialist stroke rehab in people's homes (thus improving patient choice) and thus compliance with national guidelines (including the RCP stroke guidelines, 2012.) Bed days saved from both HASU's and SU will be calculated in terms of financial saving. Actual therapy and care costs will be calculated for comparison. The rehabilitation care costs for this project are £15,924 per patient or £318,472 for the cohort of 20 patients.
The project has been set up using the predicted costs of a complex needs stroke survivor spending four weeks in an acute stroke unit (tariff £4,646) then transferred for further inpatient rehabilitation for 56 days at the cost of £280 per day . This equates to £20,326 per patient for direct in-patient care costs.
Although the overall project costs of this study exceed this figure, the service costs which would be recurrent if the model is deemed clinically and economically viable are less.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Only those with capacity to consent will be admitted into the study.
The criteria to make this decision is defined in the Community Care (Delayed Discharges) Act, 2003 as: A clinical decision has been made that the patient is ready for transfer AND a multi-disciplinary team (MDT) decision has been made that the patient is ready for transfer AND the patient is safe to discharge/transfer.
Exclusion criteria
Time frame: This will be collected prior to the start of the intervention (approx 7 days post stroke) and after 8 weeks of therapy (approx 9 weeks post stroke)
This measure will identify improvements in functional ability.
Time frame: At the start of the intervention (approx 7 days post stroke) and at the end of the 8 week intervention (approx 9 weeks post stroke)
This measure will monitor psychological status pre and post intervention.
Time frame: At the start of the intervention (approx 7 days post stroke) and at the end of the 8 week intervention (approx 9 weeks post stroke)
The Goal Attainment Scale Lite will be used to measure changes in patient reported outcome measures.
Time frame: Five days post stroke, 9 weeks post stroke and at 6 months.
A Health Economist will use this measure to calculate the impact of the Enhanced ESD service on the wider health economy.
Time frame: After 8 weeks of the intervention (approx 9 weeks post stroke)
Experience surveys have been compiled to gain insight into the experience of the Enhanced ESD service from the viewpoint of the patient, carer and staff within the service.
Time frame: Within approx 7 days of the patient's stroke and 8 weeks later (approx 9 weeks post stroke)
Carers will be asked via the participant, to complete a questionnaire to collect the following data: quality of life (EQ5D) and carer stress (Caregiver Strain Index.)
Camden Clinical Commissioning Group
Other Gov
Evaluation of the Implementation of an Enhanced ESD Service for Stroke Survivors With Moderate to Severe Impairments and the Resulting Clinical and Cost Outcomes When Compared to Similar Patients in an Unchanged Stroke Care Pathway in a Neighbouring Borough.
Acronym: EESD
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT02230852
Brain Diseases, Cardiovascular Diseases
Brussels, Brussels Capital, Belgium
View Trial DetailsNCT02425345
Arterial Occlusive Diseases, Arteriosclerosis
View Trial DetailsNCT05589402
Bone Diseases, Brain Diseases
Harlingen, Texas, United States
View Trial DetailsNCT07739030
Brain Diseases, Cardiovascular Diseases
Copenhagen, Denmark
View Trial Details